Superworth

NovoCure EPS NVCR

Diluted earnings per share by quarter and over the last twelve months, from 2014.

Last 12 months, to Sep 30, 2026
−$1.06
Latest quarter, Q3 FY26
−$0.09
Fiscal year 2025
−$1.22

NovoCure's earnings per share was −$1.06 over the twelve months to Sep 30, 2026.

In its latest quarter, Q3 FY26, it was −$0.09.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.22n/a
FY2024−$1.56n/a
FY2023−$1.94n/a
FY2022−$0.88n/a
FY2021−$0.56−395%
FY2020$0.19n/a
FY2019−$0.08n/a
FY2018−$0.70n/a
FY2017−$0.70n/a
FY2016−$1.55n/a
FY2015−$6.61n/a
FY2014n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.09n/a−$1.06
Q2 FY26−$0.13n/a−$1.30
Q1 FY26−$0.62n/a−$1.53
Q4 FY25−$0.22n/a−$1.22
Q3 FY25−$0.33n/a−$1.61
Q2 FY25−$0.36n/a−$1.56
Q1 FY25−$0.31n/a−$1.51
Q4 FY24−$0.61n/a−$1.56
Q3 FY24−$0.28n/a−$1.39
Q2 FY24−$0.31n/a−$1.57
Q1 FY24−$0.36n/a−$1.80
Q4 FY23−$0.44n/a−$1.94

Against its peers

Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.

CompanyEPS, 12 monthsGrowth
NVCRNovoCure−$1.06
EYENational Vision$0.61
CDRECadre$0.81−14% a year
LMATLemaitre Vascular$2.85+38% a year
STAAStaar Surgical$0.07
INSPInspire Medical Systems$4.62+132% a year
BVSBioventus$0.77+627% a year
UFPTUFP Technologies$9.28+8% a year
IARTIntegra Lifesciences$0.17
IRMDIradimed$1.87+13% a year
WRBYWarby Parker$0.07
Peer median$0.79

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on NovoCure

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.